Vooruitgang in monoklonale antilichamen: van laboratorium naar levensreddende therapieën

Monoclonal antibodies (mAbs) are now a fundamental component of immunology and biotechnology, with a wide range of uses in applied biology, immunology, biochemistry, and other scientific domains. The hybridoma technique, invented in 1975 by Cesar Milstein and Georges Kohler, revolutionized the production of mAbs. Since then, numerous studies have revealed a wide range of applications for monoclonal antibodies (mAbs), with clinical medicine experiencing the most significant impact. mAbs are now essential in the treatment of conditions like breast cancer, psoriasis, arthritis, leukemia, and transplant rejection. The rise in late-stage clinical trials and their expanded role in modern treatments provide evidence of their growing prominence. Biological agents have become a viable treatment option for cancer and chronic immune-mediated diseases in addition to mAbs. These medications have proven very helpful in treating allergic and immune-mediated disorders, even though they have been linked to infusion reactions and immune-related adverse effects, especially when anti-drug antibodies are involved. Additionally, these treatments are essential for improving immune surveillance against cancer. These biological agents' safety profiles are continually improving, particularly for chronic illnesses, providing patients with safer treatment options. mAbs have developed over the last thirty years from lab instruments to life-saving medications. The 1986 approval of Muromonab CD3 and the 1997 approval of Rituximab for B-cell lymphoma were significant turning points. About 60 therapeutic mAbs, including chimeric, humanized, and fully human versions, had received Food and Drug Administration (FDA) approval in March 2017. mAbs are now authorized to cure several conditions, including cancer, heart disease, and autoimmune disorders, as a result of these regulatory developments. Additionally, mAbs have shown promise in the treatment of hematologic malignancies, especially cutaneous lymphomas, with clinical trials demonstrating good efficacy and safety profiles. Their incorporation into stepwise regimens or combination therapies continues to improve treatment outcomes.